Ono-DI-004 | 87-71-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ono-DI-004
• 英文别名: 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]acetyl]cyclohexane-1-carboxylic acid
• CAS: 87-71-8
• 化学式: C₂₄H₃₈O₆
• 分子量: 422.6
• InChiKey: KWRRIFVHVJWXPU-HVCOQRSISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist
  申请人：Dore Sylvain

  公开号：US20080312326A1

  公开（公告）日：2008-12-18

  The present invention relates to the use of EP 1 receptor antagonists for the treatment of neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease, Parkinson syndrome, dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, Huntington's disease, spinocerebellar ataxia, etc.

  本发明涉及使用EP1受体拮抗剂治疗神经退行性疾病，例如阿尔茨海默病、帕金森病、帕金森综合症、痴呆、肌萎缩性侧索硬化症、进行性核上性麻痹、亨廷顿病、脊髓小脑性共济失调等。
• ENDOGENOUS REPAIR FACTOR PRODUCTION PROMOTERS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1563846A1

  公开（公告）日：2005-08-17

  It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

  它涉及一种内源性修复因子生成促进剂，它包括前列腺素（PG）12 激动剂、EP2 激动剂和 EP4 激动剂中的一种或至少两种。由于前列腺素（PG）12 促效剂、EP2 促效剂或 EP4 促效剂具有各种内源性修复因子生成加速作用、血管生成加速作用和干细胞分化诱导作用，因此可用作缺血性器官疾病（如动脉硬化闭塞症）的预防和/或治疗药物、动脉硬化闭塞症、布格病、雷诺病、心肌梗塞、心绞痛、糖尿病神经病变、椎管狭窄、脑血管意外、脑梗塞、肺动脉高压、骨折、老年痴呆症等）以及各种细胞和器官疾病的预防和/或治疗药物。
• IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST
  申请人：National University Corporation Hamamatsu University School of Medicine

  公开号：EP2305304A1

  公开（公告）日：2011-04-06

  An EP1 agonist has an immunopotentiating effect mediated by cytotoxic T lymphocyte activation and/or natural killer cell activation, and is thus useful for the prevention and/or treatment of cancers, microbial infectious diseases and the like.

  EP1 激动剂具有由细胞毒性 T 淋巴细胞活化和/或自然杀伤细胞活化介导的免疫增强作用，因此可用于预防和/或治疗癌症、微生物感染性疾病等。
• Endogenous repair factor production promoters
  申请人：Sakai Yoshiki

  公开号：US20060069018A1

  公开（公告）日：2006-03-30

  It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

  本发明涉及一种内源性修复因子生成促进剂，它包括前列腺素（PG）I2 激动剂、EP2 激动剂和 EP4 激动剂中的一种或至少两种。由于前列腺素（PG）I2 激动剂、EP2 激动剂或 EP4 激动剂具有各种内源性修复因子生成加速作用、血管生成加速作用和干细胞分化诱导作用，因此可用作缺血性器官疾病（如：动脉硬化闭塞症）的预防和/或治疗药物、动脉硬化闭塞症、布格病、雷诺病、心肌梗塞、心绞痛、糖尿病神经病变、椎管狭窄、脑血管意外、脑梗塞、肺动脉高压、骨折、老年痴呆症等）以及各种细胞和器官疾病的预防和/或治疗药物。
• Microspheres comprising ONO-1301
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2465537B1

  公开（公告）日：2016-06-29